Literature DB >> 22683405

Regulators of mammalian Hippo pathway in cancer.

Angela M Liu1, Kwong-Fai Wong, Xiaoou Jiang, Yiting Qiao, John M Luk.   

Abstract

Hippo pathway, originally discovered in Drosophila, is responsible for organ size control. The pathway is conserved in mammals and has a significant role in restraining cancer development. Regulating the Hippo pathway thus represents a potential therapeutic approach to treat cancer, which however requires deep understanding of the targeted pathway. Despite our limited knowledge on the pathway, there are increasing discoveries of new molecules that regulate and modulate the Hippo downstream signaling particularly in various solid malignancies, from extracellular stimuli or via pathway crosstalk. Herein, we discuss the roles of newly identified and key regulators that connect with core components (MST1/2, LATS1/2, SAV1, and MOB1) and downstream effector (YAP) in the Hippo pathway having an important role in cancer development and progression. Understanding of the mammalian Hippo pathway regulation may shed new insights to allow us selecting the right oncogenic targets and designing effective drugs for cancer treatments.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22683405     DOI: 10.1016/j.bbcan.2012.05.006

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  32 in total

1.  NEDD4 E3 ligase inhibits the activity of the Hippo pathway by targeting LATS1 for degradation.

Authors:  Zaidoun Salah; Sherri Cohen; Ella Itzhaki; Rami I Aqeilan
Journal:  Cell Cycle       Date:  2013-10-07       Impact factor: 4.534

2.  Downregulation of YAP inhibits proliferation and induces apoptosis in Eca-109 cells.

Authors:  Mu Cui; Zhen Li
Journal:  Exp Ther Med       Date:  2017-11-10       Impact factor: 2.447

Review 3.  Germinal center kinases in immune regulation.

Authors:  Hailei Yin; Zhubing Shi; Shi Jiao; Cuicui Chen; Wenjia Wang; Mark I Greene; Zhaocai Zhou
Journal:  Cell Mol Immunol       Date:  2012-09-10       Impact factor: 11.530

4.  An alternative DNA damage pathway to apoptosis in hematological cancers.

Authors:  John M Luk; Kun-Liang Guan
Journal:  Nat Med       Date:  2014-06       Impact factor: 53.440

5.  Expression profile and prognostic value of SAV1 in patients with pancreatic ductal adenocarcinoma.

Authors:  Lei Wang; Yu Wang; Peng-Ping Li; Rui Wang; Yue Zhu; Fang Zheng; Lin Li; Jiu-Jie Cui; Li-Wei Wang
Journal:  Tumour Biol       Date:  2016-10-17

Review 6.  The hippo pathway in heart development, regeneration, and diseases.

Authors:  Qi Zhou; Li Li; Bin Zhao; Kun-Liang Guan
Journal:  Circ Res       Date:  2015-04-10       Impact factor: 17.367

7.  LATS2 inhibits the activity of NF-κ B signaling by disrupting the interaction between TAK1 and IKKβ.

Authors:  Feng Yao; Weizheng Zhou; Chenxi Zhong; Wentao Fang
Journal:  Tumour Biol       Date:  2015-05-07

8.  Biallelic alterations of the large tumor suppressor 1 (LATS1) gene in infiltrative, but not superficial, basal cell carcinomas in a Japanese patient with nevoid basal cell carcinoma syndrome.

Authors:  Genshu Tate; Koji Kishimoto; Toshiyuki Mitsuya
Journal:  Med Mol Morphol       Date:  2014-08-14       Impact factor: 2.309

9.  Underexpression of LATS1 TSG in colorectal cancer is associated with promoter hypermethylation.

Authors:  Piotr M Wierzbicki; Krystian Adrych; Dorota Kartanowicz; Marcin Stanislawowski; Anna Kowalczyk; Janusz Godlewski; Iwona Skwierz-Bogdanska; Krzysztof Celinski; Tomasz Gach; Jan Kulig; Bartlomiej Korybalski; Zbigniew Kmiec
Journal:  World J Gastroenterol       Date:  2013-07-21       Impact factor: 5.742

Review 10.  NEDD4: a promising target for cancer therapy.

Authors:  Xiantao Ye; Lixia Wang; Bingxue Shang; Zhiwei Wang; Wenyi Wei
Journal:  Curr Cancer Drug Targets       Date:  2014       Impact factor: 3.428

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.